ELOX Stock Forecast & Price Target

Eloxx Pharma is attractive fundamentally because exaluren targets a clearly differentiated, mutation-specific mechanism in nonsense-mutation Alport syndrome, where it is the only disease-modifying therapy in development and early biopsies in 3 patients showed structural improvements in filtration slit density, collagen staining, and GBM width. The ongoing 24-patient Ph2b EXACT study, with dosed patients already enrolled and topline 16-week data expected in mid-2027, can validate whether those structural signals translate into proteinuria benefit and potentially support an accelerated regulatory path in a disease with no approved therapies. Its balance sheet adds credibility, with $62M in cash as of 2Q26 providing runway into mid-2028 and through both Alport and ADPKD readouts, while the larger nonsense-mediated ADPKD program offers meaningful upside optionality from a much bigger addressable patient population.

Eloxx Pharma is fundamentally challenged by its dependence on a single lead asset, exaluren, whose value is still tied to early-stage and small-sample clinical data rather than validated late-stage proof. The company’s Phase 2b in Alport Syndrome begins in 3Q26 with topline data by mid-2027 and final data by YE27, while an ADPKD study is not planned until 2027, leaving a long window of clinical, regulatory, and translatability risk, especially since prior data showed only one of three patients with proteinuria improvement. Financially, the company had $65.7M in pro forma cash after its June 2026 financing, does not expect profitability until 2033, and may need additional capital that could dilute shareholders, while its probability-adjusted sales estimate of ~$800M in 2038 remains highly uncertain.